Skip to main content
Erschienen in:

01.07.2007 | Leitthema

Bisphosphonate zur Behandlung tumorinduzierter Knochenveränderungen

verfasst von: PD Dr. P. Schmid

Erschienen in: Die Onkologie | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Behandlung tumorinduzierter Knochenveränderungen erfordert eine multimodale Vorgehensweise. Wesentliche Bestandteile sind dabei eine effektive antitumorale Therapie und eine langfristige Bisphosphonattherapie. Bei drohenden oder manifesten lokalen Komplikationen oder bei isolierten Knochenmetastasen finden zudem radiotherapeutische oder chirurgische Therapiemaßnahmen Anwendung. Bisphosphonate sind grundsätzlich bei allen Patienten mit Knochenmanifestationen indiziert. Ein frühzeitiger Einsatz ohne Nachweis tumorbedingter Knochenveränderungen erscheint hingegen außerhalb klinischer Studien nicht gerechtfertigt. Bisphosphonate führen zu einer signifikanten Prävention von Knochenkomplikationen und zu einer Verzögerung des Tumorfortschreitens im Skelettsystem und tragen zur Reduktion von Knochenschmerzen bei. Wenngleich der Einfluss auf das Gesamtüberleben lediglich moderat ist, hat eine konsequente multimodale Therapie von Knochenmetastasen unter Einsatz von Bisphosphonaten einen hohen Stellenwert, da sie zu einer deutlichen Reduktion der z. T. langfristigen Morbidisierung durch die tumorinduzierten Knochenveränderungen und somit zu einem Erhalt oder einer Verbesserung der Lebensqualität führt.
Literatur
1.
Zurück zum Zitat Sietsema WK, Ebetino FH, Salvagno AM et al. (1989) Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res 15: 389–396PubMed Sietsema WK, Ebetino FH, Salvagno AM et al. (1989) Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res 15: 389–396PubMed
2.
Zurück zum Zitat Green JR, Muller K, Jaeggi KA (1994) Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9: 745–751PubMedCrossRef Green JR, Muller K, Jaeggi KA (1994) Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9: 745–751PubMedCrossRef
3.
Zurück zum Zitat Fleisch H (1998) Bisphosphonates: Mechanisms of action. Endocrine Rev 29: 80–100CrossRef Fleisch H (1998) Bisphosphonates: Mechanisms of action. Endocrine Rev 29: 80–100CrossRef
4.
Zurück zum Zitat Sato M, Grasser W, Endo N et al. (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095–2105PubMedCrossRef Sato M, Grasser W, Endo N et al. (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095–2105PubMedCrossRef
5.
Zurück zum Zitat Masarachia P, Weinreb M, Balena R et al. (1996) Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19: 281–290PubMedCrossRef Masarachia P, Weinreb M, Balena R et al. (1996) Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19: 281–290PubMedCrossRef
6.
Zurück zum Zitat Rogers MJ, Brown RJ, Hodkin V et al. (1996) Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 224: 863–869PubMedCrossRef Rogers MJ, Brown RJ, Hodkin V et al. (1996) Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 224: 863–869PubMedCrossRef
7.
Zurück zum Zitat Frith JC, Monkkonen J, Blackburn GM et al. (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5’-(b, g- di-chloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12: 1358–1367PubMedCrossRef Frith JC, Monkkonen J, Blackburn GM et al. (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5’-(b, g- di-chloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12: 1358–1367PubMedCrossRef
8.
Zurück zum Zitat Luckman SP, Hughes DE, Coxon FP et al. (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581–589PubMedCrossRef Luckman SP, Hughes DE, Coxon FP et al. (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581–589PubMedCrossRef
9.
Zurück zum Zitat Gertz BJ, Holland SD, Kline WF et al. (1995) Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58: 288–298PubMedCrossRef Gertz BJ, Holland SD, Kline WF et al. (1995) Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58: 288–298PubMedCrossRef
10.
Zurück zum Zitat Van den Wyngaert T, Huizing MT, Vermorken JB (2006) Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol 17: 1197–1204CrossRef Van den Wyngaert T, Huizing MT, Vermorken JB (2006) Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol 17: 1197–1204CrossRef
11.
Zurück zum Zitat Gucalp R, Ritch P, Wiernik PH et al. (1992) Comparative study of pamidronate and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 10: 134–142PubMed Gucalp R, Ritch P, Wiernik PH et al. (1992) Comparative study of pamidronate and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 10: 134–142PubMed
12.
Zurück zum Zitat Major P, Lortholary A, Hon J et al. (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558–567PubMed Major P, Lortholary A, Hon J et al. (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558–567PubMed
13.
Zurück zum Zitat Pecherstorfer M, Herrmann Z, Body JJ et al. (1996) Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 14: 268–276PubMed Pecherstorfer M, Herrmann Z, Body JJ et al. (1996) Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 14: 268–276PubMed
14.
Zurück zum Zitat Ralston SH, Gallacher SSSJ, Patel U et al. (1989) Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 2: 1180–1182PubMedCrossRef Ralston SH, Gallacher SSSJ, Patel U et al. (1989) Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 2: 1180–1182PubMedCrossRef
15.
Zurück zum Zitat Ralston SH, Thiebaud D, Herrmann Z et al. (1997) Dose-response study of ibandronate in treatment of cancer-associated hypercalcaemia. Br J Cancer 75: 295–300PubMed Ralston SH, Thiebaud D, Herrmann Z et al. (1997) Dose-response study of ibandronate in treatment of cancer-associated hypercalcaemia. Br J Cancer 75: 295–300PubMed
16.
Zurück zum Zitat Hortobagyi GN, Theriault RL, Porter L et al. (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19, Aredia Breast Cancer Study Group. N Engl J Med 335: 1785–1791PubMedCrossRef Hortobagyi GN, Theriault RL, Porter L et al. (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19, Aredia Breast Cancer Study Group. N Engl J Med 335: 1785–1791PubMedCrossRef
17.
Zurück zum Zitat Holten-Verzantvoort AT van, Zwinderman AH, Aaronson NK et al. (1991) The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 27: 544–549PubMedCrossRef Holten-Verzantvoort AT van, Zwinderman AH, Aaronson NK et al. (1991) The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 27: 544–549PubMedCrossRef
18.
Zurück zum Zitat Elomaa I, Blomquist C, Gröhn P et al. (1993) Longterm controlled trial with disphosphonate in patients with osteolytic bone disease. Lancet 1: 146–149 Elomaa I, Blomquist C, Gröhn P et al. (1993) Longterm controlled trial with disphosphonate in patients with osteolytic bone disease. Lancet 1: 146–149
19.
Zurück zum Zitat Cascinu S, Graziano F, Alessandroni P et al. (1998) Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer 6: 139–143PubMedCrossRef Cascinu S, Graziano F, Alessandroni P et al. (1998) Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer 6: 139–143PubMedCrossRef
20.
Zurück zum Zitat Glover D, Lipton A, Keller A et al. (1994) Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. Cancer 74: 2949–2955PubMedCrossRef Glover D, Lipton A, Keller A et al. (1994) Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. Cancer 74: 2949–2955PubMedCrossRef
21.
Zurück zum Zitat Lipton A, Theriault RL, Hortobagyi GN et al. (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88: 1082–1090PubMedCrossRef Lipton A, Theriault RL, Hortobagyi GN et al. (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88: 1082–1090PubMedCrossRef
22.
Zurück zum Zitat Rosen LS, Gordon D, Antonio BS et al. (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377–387PubMed Rosen LS, Gordon D, Antonio BS et al. (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377–387PubMed
23.
Zurück zum Zitat Body JJ, Diel IJ, Lichinitser MR et al. (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14: 1399–1405PubMedCrossRef Body JJ, Diel IJ, Lichinitser MR et al. (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14: 1399–1405PubMedCrossRef
24.
Zurück zum Zitat Body JJ, Diel IJ, Lichinitzer M et al. (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90: 1133–1137PubMedCrossRef Body JJ, Diel IJ, Lichinitzer M et al. (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90: 1133–1137PubMedCrossRef
25.
Zurück zum Zitat Kohno N, Aogi K, Minami H et al. (2005) Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 23: 3314–3321PubMedCrossRef Kohno N, Aogi K, Minami H et al. (2005) Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 23: 3314–3321PubMedCrossRef
26.
Zurück zum Zitat Diel IJ, Solomayer EF, Costa SD et al. (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357–363PubMedCrossRef Diel IJ, Solomayer EF, Costa SD et al. (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357–363PubMedCrossRef
27.
Zurück zum Zitat Powles TJ, Paterson AHG, Kanis A et al. (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20: 3219–3224PubMedCrossRef Powles TJ, Paterson AHG, Kanis A et al. (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20: 3219–3224PubMedCrossRef
28.
Zurück zum Zitat Saarto T, Blomqvist C, Virkkunen P, Elomaa II (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19: 10–17PubMed Saarto T, Blomqvist C, Virkkunen P, Elomaa II (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19: 10–17PubMed
29.
Zurück zum Zitat Lahtinen R, Laakso M, Palva I et al. (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340: 1049–1052PubMedCrossRef Lahtinen R, Laakso M, Palva I et al. (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340: 1049–1052PubMedCrossRef
30.
Zurück zum Zitat McCloskey EV, Dunn JA, Kanis JA et al. (2001) Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113: 1035–1043PubMedCrossRef McCloskey EV, Dunn JA, Kanis JA et al. (2001) Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113: 1035–1043PubMedCrossRef
31.
Zurück zum Zitat Brincker H, Westin J, Abildgaard N et al. (1998) Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo- controlled trial. Danish-Swedish co-operative study group. Br J Haematol 101: 280–286PubMedCrossRef Brincker H, Westin J, Abildgaard N et al. (1998) Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo- controlled trial. Danish-Swedish co-operative study group. Br J Haematol 101: 280–286PubMedCrossRef
32.
Zurück zum Zitat Berenson JR, Lichtenstein A, Porter L et al. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488–493PubMedCrossRef Berenson JR, Lichtenstein A, Porter L et al. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488–493PubMedCrossRef
33.
Zurück zum Zitat Menssen HD, Sakalova A, Fontana A et al. (2002) Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20: 2353–2359PubMedCrossRef Menssen HD, Sakalova A, Fontana A et al. (2002) Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20: 2353–2359PubMedCrossRef
34.
Zurück zum Zitat Saad F, Gleason DM, Murray R et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879–882PubMedCrossRef Saad F, Gleason DM, Murray R et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879–882PubMedCrossRef
35.
Zurück zum Zitat Rosen LS, Gordon D, Tchekmedyian NS et al. (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100: 2613–2621PubMedCrossRef Rosen LS, Gordon D, Tchekmedyian NS et al. (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100: 2613–2621PubMedCrossRef
36.
Zurück zum Zitat Paterson AH, Powles TJ, Kanis JA et al. (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11(1):59–65PubMed Paterson AH, Powles TJ, Kanis JA et al. (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11(1):59–65PubMed
37.
Zurück zum Zitat Kristensen B, Ejlertsen B, Groenvold M et al. (1999) Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246(1):67–74PubMedCrossRef Kristensen B, Ejlertsen B, Groenvold M et al. (1999) Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246(1):67–74PubMedCrossRef
38.
Zurück zum Zitat Tubiana-Hulin M, Beuzeboc P, Mauriac L et al. (2001) Double-blind controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88(7):701PubMed Tubiana-Hulin M, Beuzeboc P, Mauriac L et al. (2001) Double-blind controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88(7):701PubMed
Metadaten
Titel
Bisphosphonate zur Behandlung tumorinduzierter Knochenveränderungen
verfasst von
PD Dr. P. Schmid
Publikationsdatum
01.07.2007
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 7/2007
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-007-1209-9

Weitere Artikel der Ausgabe 7/2007

Die Onkologie  7/2007 Zur Ausgabe

CME Weiterbildung • Zertifizierte Fortbildung

Carcinoma of unknown primary (CUP-Syndrom)

Neu im Fachgebiet Onkologie

Mit dem Alkoholentzug sinkt das Krebsrisiko

Wie die Ergebnisse einer Studie aus Frankreich nahelegen, kann sich das Risiko von alkoholabhängigen Menschen, an einem alkoholassoziierten Tumor zu erkranken, um rund 40% vermindern, wenn sie das Trinken reduzieren oder ganz einstellen.

Gemischte Befunde zur zielgerichteten Adjuvanz

23.07.2024 Melanom Nachrichten

Mit Blick auf rezidiv- und metastasenfreies Überleben bestätigen die finalen Ergebnisse der COMBI-AD-Studie die Wirksamkeit von Dabrafenib/Trametinib beim Stadium-III-Melanom. Die Effekte auf das Gesamtüberleben sind dagegen weniger klar.  

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.